Benzinga
NKGen Biotech's SNK01 NK Cell Therapy Cleared to Start Phase 2 Clinical Trial in Alzheimer's Disease - NKGen Biotech (NASDAQ:NKGN)
SANTA ANA, Calif., May 20, 2024 (GLOBE NEWSWIRE) -- NKGen Biotech, Inc. NKGN ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on the development and commercialization ...
5 days ago